Publications

Gucalp A, Zhou XK, Cook ED, Garber JE, Crew KD, Nangia JR, Bhardwaj P, Giri DD, Elemento O, Verma A et al..  2018.  A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease.. Cancer Prev Res (Phila). 11(4):203-214.

Valls E, Lobry C, Geng H, Wang L, Cardenas M, Rivas M, Cerchietti L, Oh P, Yang SNing, Oswald E et al..  2017.  BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.. Cancer Discov. 7(5):506-521.

Valls E, Lobry C, Geng H, Wang L, Cardenas M, Rivas M, Cerchietti L, Oh P, Yang SNing, Oswald E et al..  2017.  BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.. Cancer Discov. 7(5):506-521.

Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP, Helenius K, Olson BM, Pyzer AR, Wang LC et al..  2017.  Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.. Cancer Discov. 7(7):750-765.

Jiang Y, Ortega-Molina A, Geng H, Ying H-Y, Hatzi K, Parsa S, McNally D, Wang L, Doane AS, Agirre X et al..  2017.  CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.. Cancer Discov. 7(1):38-53.

Amengual JE, Prabhu SA, Lombardo M, Zullo K, Johannet PM, Gonzalez Y, Scotto L, Serrano XJirau, Wei Y, Duong J et al..  2017.  Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.. Clin Cancer Res. 23(12):3084-3096.

Allen JE, C Kline LB, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A et al..  2016.  Discovery and clinical introduction of first-in-class imipridone ONC201.. Oncotarget. 7(45):74380-74392.

Allen JE, C Kline LB, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A et al..  2016.  Discovery and clinical introduction of first-in-class imipridone ONC201.. Oncotarget. 7(45):74380-74392.

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R et al..  2016.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.. N Engl J Med. 375(5):443-53.

Cárdenas MG, Yu W, Béguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang S-N, Cohen J et al..  2016.  Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.. J Clin Invest. 126(9):3351-62.

Ortega-Molina A, Boss IW, Canela A, Pan H, Jiang Y, Zhao C, Jiang M, Hu D, Agirre X, Niesvizky I et al..  2015.  The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.. Nat Med. 21(10):1199-208.

Geyer JTurbiner, Subramaniyam S, Jiang Y, Elemento O, Ferry JA, de Leval L, Nakashima MO, Liu Y-C, Martin P, Mathew S et al..  2015.  Lymphoblastic transformation of follicular lymphoma: a clinicopathologic and molecular analysis of 7 patients.. Hum Pathol. 46(2):260-71.

Beltran H, Eng K, Mosquera JMiguel, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J et al..  2015.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.. JAMA Oncol. 1(4):466-74.

Prasain N, Lee MRyul, Vemula S, Meador JLuke, Yoshimoto M, Ferkowicz MJ, Fett A, Gupta M, Rapp BM, Saadatzadeh MReza et al..  2014.  Differentiation of human pluripotent stem cells to cells similar to cord-blood endothelial colony-forming cells.. Nat Biotechnol. 32(11):1151-1157.

Béguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SNing, Wang L, Ezponda T et al..  2013.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.. Cancer Cell. 23(5):677-92.

Bödör C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM et al..  2013.  EZH2 mutations are frequent and represent an early event in follicular lymphoma.. Blood. 122(18):3165-8.

Bödör C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM et al..  2013.  EZH2 mutations are frequent and represent an early event in follicular lymphoma.. Blood. 122(18):3165-8.

Bödör C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM et al..  2013.  EZH2 mutations are frequent and represent an early event in follicular lymphoma.. Blood. 122(18):3165-8.

Baca SC, Prandi D, Lawrence MS, Mosquera JMiguel, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M et al..  2013.  Punctuated evolution of prostate cancer genomes.. Cell. 153(3):666-77.

Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JYun Helen, Chen CX, Huang J, Beltran H, Oldridge DA, Kitabayashi N et al..  2012.  Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.. Proc Natl Acad Sci U S A. 109(17):6686-91.

Campbell TL, De Silva EK, Olszewski KL, Elemento O, Llinás M.  2010.  Identification and genome-wide prediction of DNA binding specificities for the ApiAP2 family of regulators from the malaria parasite.. PLoS Pathog. 6(10):e1001165.